Tiny engineered particles made from silica destroyed aggressive prostate tumors in mice while simultaneously activating the immune system to fight cancer — producing complete remissions in a portion of test animals when combined with immunotherapy, according to a new preclinical study led by scientists at Weill Cornell Medicine and the Cornell Duffield College of Engineering.
The results, published June 15, 2026 in the journal Cancer Research, offer some of the most striking preclinical findings reported this year for advanced prostate cancer. But researchers and oncologists are clear that laboratory results in mice do not translate automatically to humans, and that significant additional testing is needed before this approach could become a treatment option.
